Table 2 Associations between CYP17 genetic polymorphisms and breast cancer by menopausal status: Western New York Breast Cancer Study
From: CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
Case (n [%]) | Control (n [%]) | Crude odds ratio (95% CI) | Adjusted odds ratio (95% CI)a | |
|---|---|---|---|---|
Premenopausal (n = 182) | ||||
A1/A1 | 58 (61) | 48 (56) | 1.00 | 1.00 |
A1/A2 | 31 (32) | 28 (33) | 0.92(0.48–1.73) | 0.85(0.44–1.63) |
A2/A2 | 7 (7) | 10 (11) | 0.58(0.21–1.64) | 0.56(0.20–1.62) |
Postmenopausal (n = 213) | ||||
A1/A1 | 51 (46) | 47 (46) | 1.00 | 1.00 |
A1/A2 | 52 (47) | 43 (42) | 1.10 (0.63–1.90) | 0.97 (0.45–2.20) |
A2/A2 | 8 (7) | 12 (12) | 0.60 (0.23–1.60) | 0.45 (0.13–1.60) |